GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Common Stock

Orphazyme AS (CHIX:ORPHAC) Common Stock : kr35.31 Mil (As of Jun. 2022)


View and export this data going back to 2021. Start your Free Trial

What is Orphazyme AS Common Stock?

Orphazyme AS's quarterly common stock stayed the same from Jun. 2021 (kr34.95 Mil) to Dec. 2021 (kr34.95 Mil) but then increased from Dec. 2021 (kr34.95 Mil) to Jun. 2022 (kr35.31 Mil).

Orphazyme AS's annual common stock increased from Dec. 2019 (kr19.98 Mil) to Dec. 2020 (kr34.70 Mil) and increased from Dec. 2020 (kr34.70 Mil) to Dec. 2021 (kr34.95 Mil).

Orphazyme AS Common Stock Historical Data

The historical data trend for Orphazyme AS's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orphazyme AS Common Stock Chart

Orphazyme AS Annual Data
Trend Jun14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Common Stock
Get a 7-Day Free Trial 19.93 19.94 19.98 34.70 34.95

Orphazyme AS Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 27.05 34.70 34.95 34.95 35.31

Orphazyme AS Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Orphazyme AS (CHIX:ORPHAC) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Orphazyme AS (CHIX:ORPHAc) » Definitions » Common Stock
Comparable Companies
Traded in Other Exchanges
N/A
Address
Ole Maaloes Vej 3, Copenhagen, DNK, DK-2200
Website
https://www.orphazyme.com
Orphazyme AS is a late-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of neurodegenerative rare diseases. The company's lead candidate, Arimoclomol, is in development for severe orphan diseases: Niemann-Pick disease Type C (NPC), Amyotrophic Lateral Sclerosis (ALS), and Inclusion Body Myositis (IBM).

Orphazyme AS (CHIX:ORPHAC) Headlines

No Headlines